Citi analyst Samantha Semenkow downgraded Amicus (FOLD) to Neutral from Buy with a price target of $14.50, down from $17, after BioMarin BMRN) announced it will acquire Amicus for $4.8B or $14.50 per share. Citi sees low potential of another bidder emerging.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks